Efficient CRISPR-Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators
Open Access
- 21 November 2022
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 30, 621-632
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (Do491/10-1)
- Deutsche Forschungsgemeinschaft (LI3540/1-1)
- Deutsche Forschungsgemeinschaft (Do491/8-1/2)
- Deutsche Forschungsgemeinschaft (TRR130/TP24)
- Deutsche Forschungsgemeinschaft (11-1)
This publication has 35 references indexed in Scilit:
- CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer ModelingCell, 2014
- From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsetsCurrent Opinion in Immunology, 2014
- IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseasesNature, 2014
- Transcriptional Regulation of Germinal Center B and Plasma Cell Fates by Dynamical Control of IRF4Immunity, 2013
- Efficient Lentiviral Transduction and Transgene Expression in Primary Human B CellsHuman Gene Therapy Methods, 2012
- High Rate of Antibody Secretion Is not Integral to Plasma Cell Differentiation as Revealed by XBP-1 DeficiencyThe Journal of Immunology, 2012
- Efficient Human Hematopoietic Cell Transduction Using RD114- and GALV-Pseudotyped Retroviral Vectors Produced in Suspension and Serum-Free MediaHuman Gene Therapy, 2009
- An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In VivoMolecular Therapy, 2007
- Graded Expression of Interferon Regulatory Factor-4 Coordinates Isotype Switching with Plasma Cell DifferentiationImmunity, 2006
- Stable antibody expression at therapeutic levels using the 2A peptideNature Biotechnology, 2005